Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
Fiche publication
Date publication
juin 2021
Journal
Thrombosis research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
Tous les auteurs :
Deschênes-Simard X, Richard C, Galland L, Blais F, Desilets A, Malo J, Cvetkovic L, Belkaid W, Elkrief A, Gagné A, Hamel MA, Orain M, Joubert P, Ghiringhelli F, Routy B, Blais N
Lien Pubmed
Résumé
Venous thrombotic events (VTEs) are a frequent complication of non-small cell lung cancer (NSCLC) and are associated with increased morbidity. Immune checkpoint inhibitors (ICIs) are revolutionizing the management of NSCLC, but little is known about their impact on thrombosis. This study aims to define the incidence and clinical relevance of VTEs in NSCLC patients receiving these treatments.
Mots clés
Checkpoint inhibitors, Deep vein thrombosis, Immunotherapy, Non-small cell lung cancer, Pulmonary embolism, Thrombosis
Référence
Thromb Res. 2021 Jun 29;205:29-39